According to an analysis, evidence pointed to a Chinese hacking group. German drugmaker Bayer was also targeted in April, apparently by Chinese hackers who used the same malware.
A spokesperson said the data stolen would not have included patient information. A cybersecurity expert said organizations that aggregate data, like CROs, are often a target for criminals as well as foreign espionage groups, especially from China.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The partnership with the Massachusetts-based CRO could yield up to $2.4 billion in royalties for Atomwise, if projects are successful.
The report, by CRO Worldwide Clinical Trials, shows growing need for early-stage development expertise, with high demand for data quality, efficiency and overall trial management.
The U.S. House gave final approval on Thursday to a bill that would avert a 25 percent cut in Medicare payments to doctors by freezing reimbursement rates at current levels until the end of next year, reports the New York Times. President Obama, who hailed the nearly unanimous action by Congress, promised to sign the legislation.
Though presumptive House Speaker John Boehner (R-Ohio) says of health reform, "there's a lot of tricks up our sleeves in terms of how we can dent this, kick it, slow it down to make sure it never happens," it is likely the law will remain intact in a divided Congress, according to the Washington Post.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Transposagen Biopharmaceuticals Inc. signed an exclusive licensing deal with Charles River Laboratories International Inc. (NYSE:CRL) for lab rats. Under the agreement, Wilmington, Mass.-based Charles River will market and distribute the Lexington, Ky.-based lab rat developer’s p53 and Bcrp TGEM Knockout rat models, so named for mutations in their p53 and Bcrp genes. The rats mimic […]
Charles River Laboratories International Inc. (NYSE: CRL), fresh from the collapse of a proposed, $1.6 billion merger with WuXi PharmaTech (Cayman) Inc. (NYSE: WX), plans to accelerate a $300 million stock buyback and took out a $750 million credit line.
It’s been a busy week for everyone concerned with a proposed, $1.6 billion merger between Charles River Laboratories International Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX). Aiming to counter stiff opposition from some of its top institutional investors, Charles River Labs issued a revised presentation this week highlighting the benefits of the deal […]
Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal with a new investor presentation and positive responses from clients. Looking to bolster support for its proposed, $1.6 billion merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), Charles River Laboratories International Inc. (NYSE:CRL) is mounting […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Grand Court of the Cayman Islands plans to review a controversial, $1.6 billion merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL). Under the law of the Cayman Islands, where WuXi is incorporated, Grand Court approval is required to consummate the deal. WuXi said the court, equivalent to the […]
Two more top investors in Charles River Laboratories International Inc. (NYSE:CRL) voiced opposition to a proposed merger with WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal is too risky. Neuberger Berman LLC, in a June 16 letter to CRL’s board of directors, said the merger is not in the best interest of CRL’s shareholders and […]
Charles River Laboratories International Inc. (NYSE:CRL) responded to its largest shareholder’s protest about a proposed merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal was too good to pass up. In a letter to Jana Partners Inc. managing partner Barry Rosenstein, CRL CEO James Foster wrote that the hedge fund’s view of the […]